Introduction {#sec1}
============

Several hormones of the steroidal skeleton are found in biological signaling in mammals.^[@ref1],[@ref2]^ A large number of bioactive steroidal natural products have been isolated from various plants and microorganisms.^[@ref3],[@ref4]^ Numerous synthetic derivatives have also been reported in literature in a quest of drugs, drug candidates, and other valuable materials including herbicides.^[@ref5]−[@ref11]^ Natural and synthetic steroidal derivatives are known to show a number of useful pharmacological properties such as agonists of cell-surface G-protein-coupled bile acid receptor,^[@ref12]^ neuroprotective,^[@ref13]^ anticancer,^[@ref14]^ and anti-Alzheimer^[@ref15]^ properties.^[@ref7],[@ref16]^ Unnatural steroidal derivatives are one of the broadest spectra of therapeutic classes of compounds, which are used to treat different diseases including cancer.^[@ref8],[@ref17]^ Thiazole derivatives are another class of important compounds with several approved drugs such as dasatinib, fanetizole, and nizatidine.^[@ref18],[@ref19]^ Several steroidal drugs contain heterocyclic moieties: oxazole in Emflaza (deflazacort) and pyridine in Zytiga (abiraterone acetate).^[@ref20]−[@ref22]^ Thiazole-attached progesterone derivatives have been reported as potent SKOV-3 (ovarian cancer) growth inhibitor.^[@ref23]^ Pyrazole-fused sterone, stanazolol, derivative is known for potent anabolic activities ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref24]^ Not surprisingly, syntheses of heterocycle-incorporated steroidal derivatives have been reported in a large number of literature.^[@ref25]−[@ref31]^ Novel molecules based on the steroidal core structure are synthesized in a multistep synthesis^[@ref7],[@ref12],[@ref32]−[@ref34]^ and using catalyst.^[@ref29]^

![Representative examples of heterocycle containing steroidal drugs and pharmacologically active molecules.](ao-2018-028405_0001){#fig1}

Results and Discussion {#sec2}
======================

In our quest to synthesize bioactive molecules^[@ref35]−[@ref37]^ and to develop new domino reactions to synthesize heterocycles,^[@ref38],[@ref39]^ we planned the synthesis of thiazolino-androstanedione derivatives by using our recently reported methodology, the synthesis of thiazoline derivatives (**2**) by reacting thioamides with γ-bromoenones (**1**).^[@ref40]^ Reaction of 6β-bromoandrostenedione (**3**) with thiourea derivatives formed aminothiazoloandrostenone derivative (**4**) by an unexpected mechanism.^[@ref41]^ Surprisingly, reaction of thioamide derivative (**5**) with the electrophile (**3**) did not form the product in refluxing ethanol, as we expected from our previous report ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref41]^

![Synthesis of Thiazolo-androstenone Derivative (**6**)](ao-2018-028405_0004){#sch1}

To our delight, the reaction happened in hexafluoroisopropanol (HFIP) in 61% yield, and the reaction did not require an anhydrous solvent and inert atmosphere. The products formed cleanly, and the pure material was isolated simply by distilling out HFIP followed by recrystallizing with methanol ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Column chromatography was not required to obtain the pure product (**6**). After identifying the product as thiazolo-androstenone in HFIP, we carried out the reaction in different solvents including different alcohols and polar aprotic solvents: tetrahydrofuran, dimethyl sulfoxide (DMSO), and *N*,*N*-dimethylformamide (DMF); however, the reaction was not successful in any solvent except trifuoroethanol in moderate yield. Refluxing the reaction mixture in DMF gave the unidentifiable decomposed products.^[@ref42],[@ref43]^ On the basis of these observations, we can conclude that a very polar protic solvent is required for the product formation of this domino methodology, and HFIP has optimum properties for the success of this protocol.

![Reaction of Thiobenzamide with 6β-Bromoandrostenedione (**3**)](ao-2018-028405_0005){#sch2}

After establishing the optimum conditions, we reacted different thioamides with the electrophile (**3**), as shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}. Reaction of thioacetamide and 2-phenylthioacetamide with 6β-bromoandrostenone (**3**) formed the products (**7** and **8**) in 52 and 56% yields, respectively. 2-(2-Methylphenyl)thioacetamide also reacted with the electrophile (**3**) to give the benzyl derivative (**9**) in 55% yield. Substituted thiobenzamide derivatives were isolated under the established reaction conditions. *m*-Methyl- and *p*-methyl-substituted aryl products formed (**10** and **11**) in 59 and 61% yield, respectively. Similarly, 3-alkoxy-substituted products (**12** and **13**) formed in an average of 64% yield. A complex thioamide, 4-\[5-(trifluoromethyl)pyrid-2-yloxy\]thiobenzamide, did not hamper the reaction, and the product (**14**) was obtained in good yield. 4-Methoxy-substituted product (**15**) was obtained in 60% yield. Hydroxy-substituted products (**16**, **17**, and **18**) were obtained expectantly.

![Reaction of Thioamides with 6β-Bromoandrostenedione (**3**)](ao-2018-028405_0006){#sch3}

Furthermore, dihydroxy thiobenzamide also reacted smoothly to give the expected product (**19**) in 58% yield. Thus, the number and position of the electron-donating groups did not alter the outcome of the corresponding products. Products containing electron-withdrawing substituents were obtained under the established reaction conditions. 3-Fluoro-substituted thiazolo-androstenone derivative (**20**) formed in 60% yield, and 4-fluorophenyl-substituted compound (**21**) was obtained in 61% yield. 3-Chloro- and 4-chloro-substituted products (**22** and **23**) formed in an average of 50% yield. 3,5-Bischlorophenyl-substituted product (**24**) also formed accordingly. 4-Bromophenyl product (**25**) was obtained in 45% yield. 4-(Trifluoromethyl)thiobenzamide reacted with the electrophile to give the corresponding product (**26**). Very strong electron-withdrawing group containing aryl ring, such as 3-nitrothiobenzamide, also reacted with the electrophile (**3**) to give the corresponding product (**27**). Last but not least, pyridine-2-carbothioamide formed the product (**28**), albeit low yield (38%) was obtained. Thus, the nature and position of the electron-withdrawing group do effect the product formation of this methodology. Finally, the limitation we found in this methodology is that pyridine-4-carbothioamide and pyrimidine-2-carbotioamide failed to give the corresponding products (**29** and **30**). Thus, this methodology has the potential to generate a new class of novel molecules based on the fused thiazolo-androstane scaffold.

These molecules can be further transformed into new entities by simple reactions ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). 17-Hydroxy and 17-aceloxy derivatives of androstane skeleton are integral parts of drugs, hormones, natural products, and synthetic bioactive molecules.^[@ref44]−[@ref46]^ Ketone derivative (**20**) was reduced with NaBH~4~ and led stereoselectively to the corresponding hydroxy product (**31**) in an excellent yield. Further acetylation with Ac~2~O/pyridine afforded the acetylated product (**32**) in quantitative yield.

![Reduction and Acetylation of Ketone Derivative (**18**) to Generate a Library of Molecules](ao-2018-028405_0007){#sch4}

The structures of compounds (**20**, **21**, **25**, and **32**) were confirmed by single-crystal X-ray diffraction analysis, which has helped to establish the regiochemistry and stereochemistry of the reactions. Crystal structures (**20**, **21**, and **25**) have helped to confirm the regiospecificity of this methodology. The final product (**32**) confirmed the formation of substrate-controlled β-hydroxy product exclusively in NaBH~4~ reduction ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![Oak ridge thermal ellipsoid plot diagrams of **20** (CCDC 1859241), **21** (CCDC 1859222), **25** (CCDC 1861085), and **32** (CCDC 1859223).](ao-2018-028405_0002){#fig2}

Computational Analysis {#sec2.1}
----------------------

All density functional theory calculations were carried out using Gaussian 09 suite of programs.^[@ref46]^ The hybrid density functional method (M06-2X)/6-311++G(d,p) + PCM (solvent = HFIP) has been used to compute the feasibility of all four pathways. We have used polarizable continuum model (PCM) using the integral equation formalism variant as the self consistent reaction field method. This method creates solute cavity via a set of overlapping spheres. The free energy of all of the species was calculated using the PCM solvent model i.e., HFIP. The calculations were done at 1 atm pressure and 298 K.

HFIP is a very strong hydrogen bond donor, which makes hydrogen bonding with the carbonyl oxygen of the enone of β-bromoandrostenedione (**3**).^[@ref39]^ This hydrogen bonding makes the enone carbonyl group a better electrophile for the nucleophilic addition of thioacetamide, which is the key for the success of this methodology. Sulfur or nitrogen atom of thioacetamide can undergo nucleophilic addition to the carbonyl group of β-bromoandrostenedione (**3**) to form two possible intermediates, hemithioacetal (**A1**) or hemiaminal (**B1**), respectively. Both of these two reactions are endergonic, and the Gibb's free energy for the formation of hemithioacetal (**A1**, +18.72 kcal/mol) and hemiaminal (**B1**, +9.41 kcal/mol) is achieved by refluxing the reaction mixture in HFIP. These reactions for the formation of hemithioacetal (**A1**) and hemiaminal (**B1**) are reversible under the reaction condition. Hemithioacetal (**A1**) and hemiaminal (**B1**) undergo intramolecular S~N~2′ reaction to form the thiazoline regioisomers (**A2** and **B2**). This S~N~2′ reaction of hemithioacetal (**A1**) is more favorable than that of hemiaminal (**B1**) (−25.57 vs −22.07 kcal/mol). Dehydration, the final step, is more favorable for the hemithioacetal than the hemiaminal derivative (−28.01 vs −22.52 kcal/mol) to form the final products **A3** and **7**, respectively. Among the three steps for the formation of possible products, the last two steps are irreversible and exergonic ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). Hence, the less-energy barrier for the formation of hemiaminal (**B1**) in the first step is the deciding factor for the formation of the actual product (**7**). The other possible pathway (**C1** → **B2**) for the formation of expected product (**7**) is the least favorable. The expected product (**D3**) based on our previous report^[@ref40]^ is also thermodynamically not favorable ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). Probable potential energy surface for all of the possible pathways is shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}.

![Probable potential energy surface of formation of actual and expected products calculated at M06-2X/6-311++G(d,p) + PCM (solvent = HFIP).](ao-2018-028405_0003){#fig3}

![Plausible Mechanism for the Formation of Product (**7**) Using M06-2X/6-311++G(d,p) + PCM (Solvent = HFIP) Level of Theory](ao-2018-028405_0008){#sch5}

In Vitro Anticancer Studies {#sec2.2}
---------------------------

After the successful synthesis of these novel molecules, some of them have been tested against NCI-60 cancer cell lines.^[@ref47]^ Many of these compounds have shown promising activity against several cancer cell lines at 10 μM concentration. Selected growth inhibition data for compound **20** are shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. This compound has inhibited the growth of 31 of 60 cell lines with 50% growth inhibition (GI~50~) value \<2.80 μM concentration. The total growth inhibition (TGI) value is also in the low micromolar range. The compound (**20**) has also shown good lethal concentration (LC~50~) values against nine cancer cell lines. HCT-116 and SF-539 were inhibited with LC~50~ values of 7.30 and 5.90 μM concentrations, respectively.

###### Cytotoxic Data of Compound **20** against NCI-60 Cell Lines

                                **20**          
  ----------------- ----------- -------- ------ ------
  leukemia          HL-60(TB)   2.00     5.35   \>10
  K-562             1.82        9.08     \>10   
  MOLT-4            1.69        7.89     \>10   
  RPMI-8226         1.91        5.65     \>10   
  NSCLC             HOP-92      2.44     5.63   \>10
  NCI-H226          1.94        4.39     \>10   
  NCI-H460          2.79        8.27     \>10   
  NCI-H522          2.40        6.35     \>10   
  colon cancer      COLO 205    2.42     5.46   \>10
  HCT-116           1.73        3.56     7.33   
  HCT-15            1.56        4.17     \>10   
  SW-620            2.14        4.50     \>10   
  CNS cancer        SF-295      1.59     4.91   \>10
  SF-539            1.04        2.48     5.90   
  melanoma          LOX IMVI    1.74     3.36   6.47
  MALME-3M          1.80        4.13     9.48   
  SK-MEL-28         1.53        4.07     \>10   
  UACC-62           1.90        5.70     \>10   
  ovarian cancer    IGROV1      2.09     4.88   \>10
  OVCAR-3           1.92        3.79     7.47   
  SKOV-3            2.91        9.13     \>10   
  renal cancer      786-0       1.30     2.80   \>10
  ACHN              1.64        3.01     5.53   
  CAKI-1            1.87        3.76     7.57   
  RXF 393           1.41        2.94     6.14   
  TK-10             2.77        8.29     \>10   
  UO-31             1.61        2.98     5.54   
  prostate cancer   DU-145      2.01     4.13   \>10
  breast cancer     MCF7        1.78     4.26   \>10
  MDA-MB-231/ATCC   2.60        7.34     \>10   
  BT-549            2.20        8.06     \>10   
  T-47D             2.00        5.24     \>10   
  MDA-MB-468        1.95        4.27     \>10   

Colorectal cancer is the third most common cancer in men and women in the US, nevertheless, this cancer is second leading cause of cancer-related deaths in this country.^[@ref47]^ Central nervous system (CNS) cancer is one of the most lethal forms of cancer with very limited treatment options.^[@ref48]^ Our tested molecule (**20**) has shown significant activity against four colon cancer cell lines with GI~50~ values as low as 1.56 μM concentration. This molecule inhibited the growth of HCT-116 cell line with TGI and LC~50~ values 3.56 and 7.33 μM, respectively. Growths of two of the six CNS cancer cell lines were also inhibited significantly with GI~50~ values ∼1 μM concentration. In vitro growth inhibition of SF-539 cancer cell line of the CNS panel is very significant with TGI and LC~50~ values of 2.48 and 5.90 μM, respectively.

Melanoma is the most serious type of skin cancer. It is the 5--7th most common cancer in the United States, and the incidence of this cancer is increasing rapidly. Other than the skin, this cancer can also develop in the eyes and in internal organs such as the intestines.^[@ref49]^ Development of new therapeutic options is urgently needed to treat this rapidly rising malignancy.^[@ref50]^ Our lead compound (**20**) has shown promising growth inhibition activity against four melanoma cell lines with GI~50~ less than 2 μM concentration. TGI values are also in low micromolar concentration for these four melanoma cell lines. This compound also inhibited the two melanoma cell lines: LOX IMVI and MALME-3M cell lines with LC~50~ values of 6.47 and 9.48 μM, respectively. We have found several lead molecules such as **20** to generate a library of molecules to develop potent antimelanoma agents.

In addition, compound **20** has shown promising activity against four ovarian cancer cell lines with GI~50~ values at low micromolar concentration. The LC~50~ value for ovarian cancer cell line, OVCAR-3, is less than 10 μM. Renal cancer is the most common type of kidney cancer.^[@ref51]^ The fluorophenyl derivative (**20**) has shown potent activity against six cancer cell lines with GI~50~ and TGI values as low as 1.30 and 2.80 μM, respectively. Four renal cancer cell lines were inhibited with LC~50~ values less than 10 μM. Significant growth inhibition of prostate and breast cancer cell lines was also observed by this lead molecule (**20**). Complete data are shown in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b02840/suppl_file/ao8b02840_si_001.pdf). Detailed findings and mode of action of potent molecules will be reported soon.

Conclusions {#sec3}
===========

In summary, we have discovered a one-pot protocol to synthesize novel thiazolo-androstenones by using readily available starting materials and benign reaction conditions. On the basis of the availability of a number of thioamide starting materials and ease of reaction conditions, a large number of novel molecules as potent anticancer agents can be synthesized. Furthermore, these new scaffolds can be easily transformed into a variety of potential bioactive molecules. Further derivatization, structure--activity relationship, anticancer, and toxicity studies of these novel compounds are in progress and will be reported soon.

Experimental Section {#sec4}
====================

General Consideration {#sec4.1}
---------------------

All of the reactions were carried out under air atmosphere in round-bottom flasks. Solvents, reagents, and the substrate were bought from Fisher Scientific and Oakwood chemical.

Characterization {#sec4.2}
----------------

^1^H NMR and ^13^C NMR spectra were recorded with a Varian Mercury-300 MHz and Varian Mercury-75 MHz, respectively, with tetramethylsilane (TMS) as internal standard. CDCl~3~ (\>99.9%), DMSO-*d*~6~ (\>99.8%), or mixture of both were used to record NMR spectra. In some spectra, trifluoroacetic acid-*d* was also used to increase the solubility of the samples. The electrospray ionization-Fourier transform mass spectra (ESI-FTMS) were recorded using Bruker ApexII-FTMS system.

Crystals were grown in chloroform--methanol mixture for single-crystal diffraction.

General Procedure for the Synthesis of Thiazole-androstenones (**6**--**28**) {#sec4.3}
-----------------------------------------------------------------------------

A mixture of β-bromoandrostenedione (1 mmol), thioamide derivative (1.1 mmol), and sodium acetate (82 mg, 1.0 mmol) in 10 mL of hexafluoroisopropanol was refluxed for 12 h to complete the reaction. Progress of the reaction was monitored by thin-layer chromatography. After the completion of the reaction, HFIP was distilled out and methanol (10 mL) was added. The solid precipitate was filtered followed by washing with ∼10 mL of methanol and ∼20 mL of water under vacuum to afford the pure product.

Characterization Data {#sec4.4}
---------------------

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-phenyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**6**) {#sec4.4.1}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.92--7.90 (m, 2H), 7.46--7.40 (m, 3H), 5.86--5.84 (m, 1H), 3.05--2.86 (m, 2H), 2.56--2.34 (m, 2H), 2.20--1.80 (m, 6H), 1.68--1.16 (m, 7H), 1.09 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 164.2, 150.4, 136.6, 133.8, 131.6, 129.7, 128.8, 126.3, 121.4, 51.7, 48.1, 47.6, 36.7, 35.8, 34.3, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~30~NOS \[M + H\]^+^ 404.2042, found 404.2046. Yield (245 mg, 61%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,7,18-Trimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**7**) {#sec4.4.2}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 5.70--5.69 (m, 1H), 2.91--2.71 (m, 2H), 2.62 (s, 3H), 2.54--2.21 (m, 2H), 2.18--1.66 (m, 7H), 1.63--1.14 (m, 6H), 1.03 (s, 3H), 0.94 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 162.7, 148.7, 136.5, 130.9, 120.5, 51.7, 48.1, 47.6, 36.7, 35.8, 34.3, 31.3, 31.1, 30.6, 23.9, 21.8, 20.7, 19.4, 18.6, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~21~H~28~NOS \[M + H\]^+^ 342.1886, found 342.1890. Yield (177 mg, 52%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-phenyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**8**) {#sec4.4.3}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.40--7.21 (m, 5H), 5.67--5.65 (m, 1H), 4.25 (s, 2H), 2.95--2.74 (m, 2H), 2.50 (dd, *J* = 8.7, 19.1 Hz, 1H), 2.34--2.25 (m, 1H), 2.18--1.29 (m, 12H), 1.22--1.10 (m, 1H), 1.03 (s, 3H), 0.93 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 166.9, 148.9, 137.9, 136.5, 131.6, 129.0, 128.7, 127.0, 120.7, 51.7, 48.1, 47.6, 40.7, 36.7, 35.8, 34.3, 31.3, 31.1, 30.6, 24.0, 21.8, 20.7, 18.6, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~27~H~32~NOS \[M + H\]^+^ 418.2199, found 418.2192. Yield (233 mg, 56%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-(*o*-tolylmethyl)-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-one (**9**) {#sec4.4.4}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.27--7.22 (m, 4H), 5.63--5.62 (m, 1H), 4.25 (s, 2H), 2.95--2.74 (m, 2H), 2.49 (dd, *J* = 8.7, 19.2 Hz, 1H), 2.34 (s, 3H), 2.34--2.28 (m, 1H), 2.17--1.78 (m, 7H), 1.58--1.14 (m, 6H), 1.03 (s, 3H), 0.93 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 167.3, 148.8, 136.7, 136.5, 136.3, 131.3, 130.5, 130.0, 127.5, 126.3, 120.6, 51.7, 48.1, 47.6, 37.8, 36.6, 35.8, 34.3, 31.3, 31.1, 30.6, 24.0, 21.8, 20.7, 19.6, 18.6, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~27~H~32~NOS \[M + H\]^+^ 432.2356, found 432.2349. Yield (237 mg, 55%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-(*m*-tolyl)-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**10**) {#sec4.4.5}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.76 (s, 1H), 7.69 (d, *J* = 7.6 Hz, 1H), 7.33--7.28 (m, 1H), 7.21 (d, *J* = 7.4 Hz, 1H), 5.85--5.84 (m, 1H), 3.05--2.82 (m, 2H), 2.55--2.34 (m, 5H), 2.19--1.80 (m, 7H), 1.68--1.25 (m, 5H), 1.22--1.16 (m, 1H), 1.09 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.7, 164.4, 150.4, 138.6, 136.6, 133.7, 131.4, 130.5, 128.7, 126.8, 123.6, 121.3, 51.7, 48.2, 47.6, 36.7, 35.8, 34.3, 31.4, 31.1, 30.8, 24.1, 21.8, 21.3, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~27~H~32~NOS \[M + H\]^+^ 418.2199, found 418.2204. Yield (246 mg, 59%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-(*p*-tolyl)-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**11**) {#sec4.4.6}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.80 (d, *J* = 8.0 Hz, 2H), 7.23 (d, *J* = 8.2 Hz, 2H), 5.83--5.52 (m, 1H), 3.03--2.87 (m, 2H), 2.55--2.33 (m, 2H), 2.39 (s, 3H), 2.19--1.80 (m, 7H), 1.68--1.15 (m, 6H), 1.08 (s, 3H), 0.94 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 164.5, 150.2, 140.0, 136.6, 131.1, 129.5, 126.3, 121.2, 51.7, 48.1, 47.6, 36.7, 35.8, 34.3, 31.3, 31.1, 30.8, 24.1, 21.8, 21.4, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~27~H~32~NOS \[M + H\]^+^ 418.2199, found 418.2204. Yield (254 mg, 61%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3-Methoxyphenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**12**) {#sec4.4.7}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.47 (m, 2H), 7.32 (d, *J* = 8.2 Hz, 1H), 6.95--6.92 (m, 1H), 5.83 (s, 1H), 3.87 (s, 3H), 3.02--2.80 (m, 2H), 2.53--2.33 (m, 2H), 2.17--1.78 (m, 6H), 1.65--1.13 (m, 7H), 1.06 (s, 3H), 0.92 (m, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.7, 164.0, 159.9, 150.3, 136.5, 135.1, 131.7, 129.8, 121.5, 119.0, 116.0, 110.9, 55.4, 51.6, 48.1, 47.5, 36.7, 35.8, 34.3, 31.3, 31.1, 30.7, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~27~H~32~NO~2~S \[M + H\]^+^ 434.2148, found 434.2154. Yield (286 mg, 66%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3-Ethoxyphenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**13**) {#sec4.4.8}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.48--7.47 (m, 2H), 7.32 (t, *J* = 5.1 Hz, 1H), 6.94 (dd, *J* = 2.4, 8.3 Hz, 1H), 5.86--5.85 (m, 1H), 4.12 (q, *J* = 3.9 Hz, 2H), 3.04--2.82 (m, 2H), 2.56--2.34 (m, 2H), 2.20--1.81 (m, 7H), 1.71--1.20 (m, 9H), 1.09 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 164.1, 159.3, 150.4, 136.6, 135.1, 131.6, 129.8, 121.4, 118.8, 116.5, 111.6, 63.6, 51.7, 48.1, 47.6, 36.7, 35.8, 34.3, 31.4, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 14.8, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~28~H~34~NO~2~S \[M + H\]^+^ 448.2305, found 448.2301. Yield (291 mg, 62%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-\[3-\[\[5-(trifluoromethyl)-2-pyridyl\]oxy\]phenyl\]-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-one (**14**) {#sec4.4.9}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 8.47 (s, 1H), 7.99--7.92 (m, 3H), 7.21 (d, *J* = 8.4 Hz, 2H), 7.07 (d, *J* = 8.5 Hz, 1H), 5.86--5.85 (m, 1H), 3.04--3.02 (m, 2H), 2.56--2.35 (m, 2H), 2.20--1.19 (m, 13H), 1.09 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.9, 165.4, 163.2, 154.2, 150.5, 145.5 (*J* = 4.3 Hz), 136.8, 136.5, 131.7, 131.2, 127.9, 125.4, 122.1, 121.8, 121.7, 121.6, 111.6, 51.7, 48.1, 47.6, 36.7, 35.8, 34.3, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~32~H~32~N~2~O~2~F~3~S \[M + H\]^+^ 565.2131, found 565.2125. Yield (366 mg, 65%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(4-Methoxyphenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**15**) {#sec4.4.10}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.86 (d, *J* = 8.6 Hz, 2H), 6.94 (d, *J* = 8.7 Hz, 2H), 5.82--5.81 (m, 1H), 3.86 (s, 3H), 3.02--2.86 (m, 2H), 2.55--2.33 (m, 2H), 2.19--1.81 (m, 6H), 1.68--1.16 (m, 7H), 1.09 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.7, 164.2, 160.9, 150.2, 136.7, 130.6, 127.8, 126.8, 120.9, 114.2, 55.3, 51.7, 48.2, 47.6, 36.7, 35.8, 34.3, 31.4, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~27~H~32~NO~2~S \[M + H\]^+^ 434.2148, found 434.2153. Yield (259 mg, 60%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3-Hydroxy)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**16**) {#sec4.4.11}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~ + DMSO-*d*~6~) δ ppm: 12.13 (br s, 1H), 7.49 (d, *J* = 7.7 Hz, 1H), 7.19 (t, *J* = 8.2 Hz, 1H), 6.88 (d, *J* = 8.2 Hz, 1H), 6.81 (t, *J* = 7.4 Hz, 1H), 5.78 (br s, 1H), 2.87--2.74 (m, 2H), 2.51--2.31 (m, 2H), 2.07--1.71 (m, 6H), 1.60--1.12 (m, 7H), 0.98 (s, 3H), 0.84 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~ + DMSO-*d*~6~) δ ppm: 220.3, 164.9, 156.6, 147.6, 135.6, 130.9, 129.2, 126.7, 121.7, 118.8, 117.2, 116.7, 51.2, 47.6, 47.1, 36.3, 35.3, 33.6, 30.9, 30.7, 30.3, 23.2, 21.4, 20.3, 18.3, 13.2. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~NOS \[M + H\]^+^ 420.1992, found 420.1997. Yield (230 mg, 55%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3-Hydroxy)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**17**) {#sec4.4.12}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~ + DMSO-*d*~6~) δ ppm: 9.41 (d, *J* = 5.2 Hz, 1H), 7.27--7.13 (m, 3H), 6.77 (d, *J* = 7.9 Hz, 1H), 5.77 (s, 1H), 2.89--2.70 (m, 2H), 2.43--2.30 (m, 2H), 2.04--1.72 (m, 6H), 1.60--1.11 (m, 7H), 0.99 (s, 3H), 0.84 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~ + DMSO*-d*~6~) δ ppm: 219.7, 163.4, 158.0, 150.3, 136.3, 134.8, 131.4, 130.1, 121.9, 117.3, 117.1, 112.9, 51.4, 48.0, 47.3, 36.6, 35.7, 34.1, 31.4, 31.0, 30.7, 24.1, 21.8, 20.7, 18.8, 13.7. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~30~NO~2~S \[M + H\]^+^ 420.1992, found 420.1989. Yield (273 mg, 65%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(4-Hydroxy)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**18**) {#sec4.4.13}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~ + DMSO-*d*~6~) δ ppm: 9.90 (s, 1H), 7.67 (d, *J* = 8.3 Hz, 2H), 6.81 (d, *J* = 8.3 Hz, 2H), 5.74 (s, 1H), 2.85--2.69 (m, 2H), 2.50--2.27 (m, 2H), 2.06--1.71 (m, 6H), 1.62--1.15 (m, 7H), 1.00 (s, 3H), 0.84 (s, 3H); ^1^H NMR (300 MHz, CDCl~3~ + DMSO-*d*~6~) δ ppm: 219.7, 163.8, 159.7, 150.1, 136.5, 130.0, 127.9, 125.0, 121.5, 116.1, 51.3, 48.0, 47.3, 36.6, 35.7, 34.2, 31.5, 31.0, 30.6, 24.2, 21.8, 20.7, 18.9, 13.7. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~NO~2~S \[M + H\]^+^ 420.1992, found 420.1997. Yield (281 mg, 67%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3,4-Dihydroxyphenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-one (**19**) {#sec4.4.14}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~ + DMSO-*d*~6~) δ ppm: 8.95 (s, 1H), 8.78 (s, 1H), 7.30 (d, *J* = 2.0 Hz, 1H), 7.13 (dd, *J* = 2.0, 8.1 Hz, 1H), 6.74 (d, *J* = 8.2 Hz, 1H), 5.68 (br s, 1H), 2.83--2.71 (m, 2H), 2.50--2.29 (m, 3H), 2.07--1.73 (m, 6H), 1.56--1.12 (m, 6H), 0.98 (s, 3H), 0.84 (s, 3H); ^1^H NMR (75 MHz, CDCl~3~ + DMSO-*d*~6~) δ ppm: 220.1, 164.2, 149.8, 147.6, 145.5, 136.4, 130.0, 125.7, 120.9, 118.2, 115.9, 113.6, 51.4, 48.0, 47.4, 36.6, 35.7, 34.2, 31.4, 31.0, 30.6, 24.1, 21.7, 20.6, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~30~NO~3~S \[M + H\]^+^ 436.1941, found 436.1927. Yield (252 mg, 58%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3-Fluorophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**20**) {#sec4.4.15}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.69 (m, 2H), 7.42--7.35 (m, 1H), 7.12--7.06 (m, 1H), 5.88--5.85 (m, 1H), 3.04--2.88 (m, 2H), 2.53--2.11 (m, 2H), 2.08--1.81 (m, 7H), 1.69--1.20 (m, 6H), 1.09 (s, 3H), 0.95 (s, 3H); ^1^H NMR (75 MHz, CDCl~3~) δ ppm: 220.6, 163.0 (^1^*J*~CF~ = 244.9 Hz), 162.5, 150.7, 136.5, 135.9 (^3^*J*~CF~ = 8.0 Hz), 132.3, 130.4 (^3^*J*~CF~ = 8.3 Hz), 122.0, 121.9, 116.5 (^2^*J*~CF~ = 21.3 Hz), 113.0 (^2^*J*~CF~ = 23.3 Hz), 51.7, 48.1, 47.6, 36.7, 35.8, 34.2, 31.4, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~FNOS \[M + H\]^+^ 422.1948, found 422.1951. Yield (252 mg, 60%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(4-Fluorophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**21**) {#sec4.4.16}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.91--7.87 (m, 2H), 7.11 (t, *J* = 8.5 Hz, 2H), 5.84--5.83 (m, 1H), 3.03--2.86 (m, 2H), 2.56--2.34 (m, 2H), 2.20--1.80 (m, 7H), 1.68--1.18 (m, 6H), 1.08 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 163.6 (^1^*J*~CF~ = 248.6 Hz), 162.9, 150.4, 136.5, 131.7, 130.2, 128.2 (^3^*J*~CF~ = 8.3 Hz), 121.5, 116.0 (^2^*J*~CF~ = 21.8 Hz), 51.7, 48.1, 47.6, 36.7, 35.8, 34.3, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~FNOS \[M + H\]^+^ 422.1948, found 422.1953. Yield (256 mg, 61%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3-Chlorophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**22**) {#sec4.4.17}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.93 (s, 1H), 7.79--7.75 (m, 1H), 2.36--7.32 (m, 2H), 5.88--5.87 (m, 1H), 3.04--2.81 (m, 2H), 2.56--2.34 (m, 2H), 2.20--1.81 (m, 6H), 1.66--1.32 (m, 6H), 1.26--1.19 (m, 1H), 1.08 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 162.3, 150.7, 136.4, 135.4, 134.9, 132.4, 130.1, 129.6, 126.2, 124.4, 122.0, 51.7, 48.1, 47.6, 36.7, 35.8, 34.2, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~ClNOS \[M + H\]^+^ 438.1653, found 438.1654. Yield (214 mg, 49%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(4-Chlorophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-one (**23**) {#sec4.4.18}

Recrystallized from acetonitrile. Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.85 (d, *J* = 8.4 Hz, 2H), 7.40 (*J* = 8.5 Hz, 2H), 5.86--5.85 (m, 1H), 3.03--2.87 (m, 2H), 2.56--2.37 (m, 2H), 2.20--1.80 (m, 6H), 1.65--1.34 (m, 6H), 1.26--1.21 (m, 1H), 1.08 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.7, 162.7, 150.6, 136.5, 135.5, 132.3, 132.0, 129.0, 127.5, 121.8, 51.7, 48.1, 47.6, 36.7, 35.8, 34.2, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~ClNOS \[M + H\]^+^ 438.1653, found 438.1656. Yield (222 mg, 51%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(3,5-Dichlorophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-one (**24**) {#sec4.4.19}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.80--7.73 (d, *J* = 1.8 Hz, 2H), 7.37 (t, *J* = 1.8 Hz, 1H), 5.89--5.88 (m, 1H), 3.02--2.87 (m, 2H), 2.56--2.35 (m, 2H), 2.20--1.81 (m, 7H), 1.69--1.20 (m, 6H), 1.08 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.7, 160.6, 150.9, 136.49, 136.40, 135.5, 133.1, 129.2, 124.5, 122.5, 51.7, 48.1, 47.6, 36.7, 35.8, 34.2, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~28~Cl~2~NOS \[M + H\]^+^ 442.1263, found 472.1264. Yield (188 mg, 40%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-7-(4-Bromophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**25**) {#sec4.4.20}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.78 (d, *J* = 8.3 Hz, 2H), 7.55 (d, *J* = 8.3 Hz, 2H), 5.86--5.85 (m, 1H), 3.03--2.87 (m, 2H), 2.56--2.33 (m 2H), 2.20--1.81 (m, 6H), 1.68--1.31 (m, 6H), 1.26--1.17 (m, 1H), 1.08 (s, 3H), 0.95 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 222.2, 164.2, 152.1, 138.0, 134.2, 133.6, 133.5, 129.2, 125.3, 123.3, 53.1, 49.6, 49.0, 38.2, 37.3, 35.7, 32.8, 32.6, 32.3, 25.6, 23.3, 22.2, 20.1, 15.1. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~BrNOS \[M + H\]^+^ and \[M + 2 + H\]^+^ 482.1148, 484.1128, found 482.1149, 484.1129 respectively. Yield (216 mg, 45%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-\[4-(trifluoromethyl)phenyl\]-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**26**) {#sec4.4.21}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 8.02 (d, *J* = 8.1 Hz, 2H), 7.68 (d, *J* = 8.2 Hz, 2H), 5.91--5.89 (m, 1H), 3.07--2.84 (m, 2H), 2.57--2.39 (m, 2H), 2.21--1.82 (m, 7H), 1.69--1.19 (m, 6H), 1.09 (s, 3H), 0.96 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.8, 162.0, 151.0, 136.9, 136.4, 132.9, 131.3, 130.9, 126.4, 125.9--125.7 (m), 122.3, 51.7, 48.1, 47.6, 36.7, 35.8, 34.2, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~27~H~29~NOSF~3~ \[M + H\]^+^ 472.1916, found 472.1910. Yield (268 mg, 57%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-(3-nitrophenyl)-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-one (**27**) {#sec4.4.22}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 8.74 (s, 1H), 8.24 (d, *J* = 7.7 Hz, 2H), 7.61 (t, *J* = 7.9 Hz, 1H), 5.93--5.91 (m, 1H), 305--2.84 (m, 2H), 2.57--2.37 (m, 2H), 2.21--1.82 (m, 7H), 1.70--1.25 (m, 6H), 1.10 (s, 3H), 0.96 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.2, 160.4, 150.6, 148.1, 135.9, 135.0, 132.8, 131.2, 129.4, 123.4, 122.2, 120.6, 51.2, 47.6, 47.1, 36.3, 35.3, 33.7, 30.9, 30.6, 30.4, 23.6, 21.3, 20.3, 18.2, 13.2. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~29~NOS \[M + H\]^+^ 449.1893, found 449.1891. Yields (246 mg, 0.55 mmol, 55%).

### (1*S*,2*R*,13*R*,14*S*,18*S*)-2,18-Dimethyl-7-(2-pyridyl)-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),7,10-trien-17-one (**28**) {#sec4.4.23}

Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 8.59 (s, 1H), 8.13 (d, *J* = 7.6 Hz, 1H), 7.76 (t, *J* = 7.5 Hz, 1H), 7.27 (s, 1H), 5.94 (s, 1H), 3.02--2.84 (m, 2H), 2.54--2.38 (m, 2H), 2.18--1.79 (m, 7H), 1.67--1.20 (m, 6H), 1.07 (s, 3H), 0.93 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 220.7, 164.8, 151.5, 150.8, 149.4, 136.8, 136.6, 133.9, 124.0, 122.2, 119.3, 51.7, 48.1, 47.5, 36.6, 35.8, 34.3, 31.3, 31.1, 30.8, 24.1, 21.8, 20.7, 18.7, 13.6. HRMS (ESI-FTMS, *m*/*z*): calcd for C~25~H~29~N~2~OS \[M + H\]^+^ 405.1995, found 405.2000. Yield (153 mg, 38%).

### (1*S*,2*R*,13*R*,14*S*,17*S*,18*S*)-7-(4-Fluorophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-ol (**31**) {#sec4.4.24}

A solution of compound **20** (210.5 mg, 0.5 mmol) in methanol was cooled in ice and NaBH~4~ (189 mg, 5 mmol) was added portionwise, and the reaction mixture was stirred for 8 h. After completion of the reaction, aqueous 10% HCl was added, and the reaction was stirred for 2 h to precipitate the product. Filtration and washing with water gave the pure product (203 mg, 96%). Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.69--7.63 (m, 1H), 7.42--7.34 (m, 1H), 7.12--7.05 (m, 1H), 5.85--5.83 (m, 1H), 3.69 (t, *J* = 8.3 Hz, 1H), 3.04--2.81 (m, 2H), 2.31--2.22 (m, 1H), 2.18--2.05 (m, 2H), 1.93--1.28 (m, 10H), 1.22--1.11 (m, 3H), 1.07 (s, 3H), 0.82 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 163.5 (^1^*J* = 244.9 Hz), 162.4 (^4^*J* = 3.1 Hz), 150.5, 136.3, 135.9 (^3^*J* = 8.0 Hz), 132.5, 130.4 (^3^*J* = 8.2 Hz), 122.6, 122.1 (^4^*J* = 2.8 Hz), 116.5 (^2^*J* = 21.1 Hz), 113.1 (^2^*J* = 23.3 Hz), 81.7, 51.3, 48.1, 42.8, 36.7, 36.5, 34.3, 31.5, 31.5, 30.5, 24.1, 23.4, 21.0, 18.7, 11.0. HRMS (ESI-FTMS, *m*/*z*): calcd for C~26~H~30~NOS \[M + H\]^+^ 428.2105, found 424.2107. Yield (407 mg, 96%).

### \[(1*S*,2*R*,13*R*,14*S*,17*S*,18*S*)-7-(3-Fluorophenyl)-2,18-dimethyl-8-thia-6-azapentacyclo\[11.7.0.02,10.05,9.014,18\]icosa-5(9),6,10-trien-17-yl\] acetate (**32**) {#sec4.4.25}

A solution of compound **31** (150 mg, 0.35 mmol) in dichloromethane (CH~2~Cl~2~, 4 mL) was cooled in ice and acetic anhydride (1 mL) and pyridine (0.2 mL) were added, and reaction mixture was stirred for 24 h at room temperature. After the completion of the reaction, CH~2~Cl~2~ was removed by evaporation and 5 mL of methanol was added to the reaction mixture followed by adding 10 mL of water. The precipitate was filtered and washed with water to get the pure product (158 mg, 0.34 mmol, 96%). Yellowish solid, ^1^H NMR (300 MHz, CDCl~3~) δ ppm: 7.68--7.62 (m, 2H), 7.42--7.34 (m, 1H), 7.00 (dd, *J* = 2.4, 9.0 Hz, 1H), 5.85--5.83 (m, 1H), 4.64 (t, *J* = 8.0 Hz, 1H), 3.03--2.81 (m, 2H), 2.32--2.11 (m, 3H), 2.07 (s, 3H), 1.87--1.68 (m, 6H), 1.61--1.09 (m, 6H), 1.06 (s, 3H), 0.86 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~) δ ppm: 171.2, 163.0 (^1^*J* = 244.8 Hz), 162.4 (^4^*J* = 3.0 Hz), 150.6, 136.4, 136.0 (^3^*J* = 8.0 Hz), 132.5, 130.4 (^3^*J* = 8.2 Hz), 122.4, 122.0 (^4^*J* = 2.9 Hz), 116.4 (^2^*J* = 21.3 Hz), 113.1 (^2^*J* = 23.2 Hz), 82.6, 77.2, 51.0, 47.9, 42.4, 36.6, 34.3, 31.4, 31.3, 27.5, 24.1, 23.5, 21.2, 20.9, 18.7, 12.0. HRMS (ESI-FTMS, *m*/*z*): calcd for C~28~H~33~FNO~2~S \[M + H\]^+^ 466.2211, found 466.2214.
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